TMEM102 and prostate cancer: A cisplatin-loaded CNH fused to a monoclonal antibody (mAb) D2B that targets prostate specific membrane antigen (PSMA) + prostate cancer cells has been demonstrated to be more effective and selective than other hybrids in killing PSMA + prostate cancer cells.